
CareDx (CDNA) Stock Forecast & Price Target
CareDx (CDNA) Analyst Ratings
Bulls say
CareDx is poised for growth due to strong revenue growth and expansion into new markets, and their recent resolution of a Medicare issue has increased investor confidence. While competition and challenges in introducing new products should be monitored, the company's strategic acquisitions and plans for future growth make them a promising investment.
Bears say
CareDx is expected to generate revenue growth in the coming quarters through increased volume and adoption of its testing services and products in the transplant market, primarily driven by its artificial intelligence-based AlloHeme product designed to monitor cancer relapse in post-transplant patients. However, there may be potential integration risks and challenges in adoption of these products by clinicians and healthcare administrators, as well as the need for continued education and awareness. The success and potential revenue impact of the recent Naveris acquisition is also uncertain. Overall, the outlook appears positive but with some potential challenges and uncertainties.
This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares